It includes hormone-positive/HER2-negative (HR+/HER2-) breast cancers that have spread to nearby tissues or lymph nodes to small (<2 cm) early-stage triple-negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and breast carcinoma.